http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103170012-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2420-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-966 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-915 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M31-00 |
| filingDate | 2005-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103170012-B |
| titleOfInvention | Local vascular delivery of 2‑methoxyestradiol in combination with rapamycin to prevent restenosis after vascular injury |
| abstract | A medical device, particularly an implantable medical device, may be coated to minimize or substantially eliminate the biological response of the implantation of the medical device into an organism. The medical device can be coated with a number of biocompatible materials. The biocompatible material can be mixed with a therapeutic drug, agent or compound and attached to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce the biological response of the medical device implanted into the living organism. In addition, these therapeutic drugs, agents and/or compounds can be used to promote healing, including blood clotting. At the same time, the device can be modified to promote endothelialization. Various materials and coating methods can be used to retain drugs, agents or compounds on the medical device until delivered and localized. Additionally, devices used to deliver implantable medical devices may be modified to reduce the likelihood of damage to the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular rings, sutures and staples. In addition, various polymeric compositions can be used to control the rate of dissolution of therapeutic agents, agents and/or compounds from implantable medical devices. |
| priorityDate | 2004-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 529.